146 related articles for article (PubMed ID: 10090788)
21. Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor.
Geldenhuys WJ; Kuzenko SR; Simmons MA
J Med Chem; 2010 Nov; 53(22):8080-8. PubMed ID: 21047106
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
Reavill C; Taylor SG; Wood MD; Ashmeade T; Austin NE; Avenell KY; Boyfield I; Branch CL; Cilia J; Coldwell MC; Hadley MS; Hunter AJ; Jeffrey P; Jewitt F; Johnson CN; Jones DN; Medhurst AD; Middlemiss DN; Nash DJ; Riley GJ; Routledge C; Stemp G; Thewlis KM; Trail B; Vong AK; Hagan JJ
J Pharmacol Exp Ther; 2000 Sep; 294(3):1154-65. PubMed ID: 10945872
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.
Megens AA; Ashton D; Vermeire JC; Vermote PC; Hens KA; Hillen LC; Fransen JF; Mahieu M; Heylen L; Leysen JE; Jurzak MR; Janssens F
J Pharmacol Exp Ther; 2002 Aug; 302(2):696-709. PubMed ID: 12130734
[TBL] [Abstract][Full Text] [Related]
24. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
Hale JJ; Mills SG; MacCoss M; Finke PE; Cascieri MA; Sadowski S; Ber E; Chicchi GG; Kurtz M; Metzger J; Eiermann G; Tsou NN; Tattersall FD; Rupniak NM; Williams AR; Rycroft W; Hargreaves R; MacIntyre DE
J Med Chem; 1998 Nov; 41(23):4607-14. PubMed ID: 9804700
[TBL] [Abstract][Full Text] [Related]
25. Molecular and pharmacological characterization of a functional tachykinin NK3 receptor cloned from the rabbit iris sphincter muscle.
Medhurst AD; Hirst WD; Jerman JC; Meakin J; Roberts JC; Testa T; Smart D
Br J Pharmacol; 1999 Oct; 128(3):627-36. PubMed ID: 10516642
[TBL] [Abstract][Full Text] [Related]
26. Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1).
Peretto I; Forlani R; Fossati C; Giardina GA; Giardini A; Guala M; La Porta E; Petrillo P; Radaelli S; Radice L; Raveglia LF; Santoro E; Scudellaro R; Scarpitta F; Bigogno C; Misiano P; Dondio GM; Rizzi A; Armani E; Amari G; Civelli M; Villetti G; Patacchini R; Bergamaschi M; Delcanale M; Salcedo C; Fernández AG; Imbimbo BP
J Med Chem; 2007 Apr; 50(7):1571-83. PubMed ID: 17352462
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of novel fluoro and iodo quinoline carboxamides as potential ligands of NK-3 receptors for in vivo imaging studies.
Bennacef I; Tymciu S; Dhilly M; Lasne MC; Debruyne D; Perrio C; Barré L
Bioorg Med Chem; 2004 Aug; 12(16):4533-41. PubMed ID: 15265501
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
Cascieri MA; Shiao LL; Mills SG; MacCoss M; Swain CJ; Yu H; Ber E; Sadowski S; Wu MT; Strader CD
Mol Pharmacol; 1995 Apr; 47(4):660-5. PubMed ID: 7536886
[TBL] [Abstract][Full Text] [Related]
29. MEN16132, a novel potent and selective nonpeptide antagonist for the human bradykinin B2 receptor. In vitro pharmacology and molecular characterization.
Cucchi P; Meini S; Bressan A; Catalani C; Bellucci F; Santicioli P; Lecci A; Faiella A; Rotondaro L; Giuliani S; Giolitti A; Quartara L; Maggi CA
Eur J Pharmacol; 2005 Dec; 528(1-3):7-16. PubMed ID: 16324696
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor.
Bosch MP; Campos F; Niubó I; Rosell G; Díaz JL; Brea J; Loza MI; Guerrero A
J Med Chem; 2004 Jul; 47(16):4041-53. PubMed ID: 15267242
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of new 4-heteroaryl-2-phenylquinolines and their pharmacological activity as NK-2/NK-3 receptor ligands.
Borioni A; Mustazza C; Sestili I; Sbraccia M; Turchetto L; Del Giudice MR
Arch Pharm (Weinheim); 2007 Jan; 340(1):17-25. PubMed ID: 17206605
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological characterization of cloned human NK-2 (neurokinin A) receptor expressed in a baculovirus/Sf-21 insect cell system.
Aharony D; Little J; Powell S; Hopkins B; Bundell KR; McPheat WL; Gordon RD; Hassall G; Hockney R; Griffin R
Mol Pharmacol; 1993 Aug; 44(2):356-63. PubMed ID: 8394992
[TBL] [Abstract][Full Text] [Related]
33. New quinoline NK3 receptor antagonists with CNS activity.
Smith PW; Wyman PA; Lovell P; Goodacre C; Serafinowska HT; Vong A; Harrington F; Flynn S; Bradley DM; Porter R; Coggon S; Murkitt G; Searle K; Thomas DR; Watson JM; Martin W; Wu Z; Dawson LA
Bioorg Med Chem Lett; 2009 Feb; 19(3):837-40. PubMed ID: 19117759
[TBL] [Abstract][Full Text] [Related]
34. Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors.
Engberg S; Ahlstedt I; Leffler A; Lindström E; Kristensson E; Svensson A; Påhlman I; Johansson A; Drmota T; von Mentzer B
Biochem Pharmacol; 2007 Jan; 73(2):259-69. PubMed ID: 17097619
[TBL] [Abstract][Full Text] [Related]
35. NK1 receptor-mediated endothelium-dependent relaxation and contraction with different sensitivity to post-receptor signaling in pulmonary arteries.
Miike T; Shirahase H; Kanda M; Kunishiro K; Kurahashi K
Vascul Pharmacol; 2009; 51(2-3):147-53. PubMed ID: 19539781
[TBL] [Abstract][Full Text] [Related]
36. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.
Nordquist RE; Durkin S; Jacquet A; Spooren W
Eur J Pharmacol; 2008 Dec; 600(1-3):87-92. PubMed ID: 18930726
[TBL] [Abstract][Full Text] [Related]
37. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation.
Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Inamura N; Asano M; Aramori I; Hatori C; Sawai H; Oku T; Tanaka H
J Med Chem; 1998 Nov; 41(23):4587-98. PubMed ID: 9804698
[TBL] [Abstract][Full Text] [Related]
38. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms mediating substance P-induced contraction in the rat iris in vitro.
Grumann-Júnior A; Dias MA; Alves RV; Boteon JE; Calixto JB
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1861-70. PubMed ID: 10845610
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
